NeuroSense Therapeutics (NRSN)
(Delayed Data from NSDQ)
$1.23 USD
-0.03 (-2.38%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $1.23 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for NeuroSense Therapeutics Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 13 | 14 | 6 | 3 | 1 |
Income After Depreciation & Amortization | -13 | -14 | -6 | -3 | -1 |
Non-Operating Income | 4 | 1 | 3 | 0 | 0 |
Interest Expense | 2 | 0 | 1 | 0 | 0 |
Pretax Income | -11 | -12 | -4 | -3 | -1 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -11 | -12 | -4 | -3 | -1 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -11 | -12 | -4 | -3 | -1 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -13 | -13 | -6 | -3 | -1 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -13 | -14 | -6 | -3 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 13.59 | 11.51 | 6.24 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.83 | -1.07 | -0.65 | NA | NA |
Diluted Net EPS (GAAP) | -0.83 | -1.07 | -0.65 | -0.51 | NA |
Fiscal Year end for NeuroSense Therapeutics Ltd falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | NA | NA | NA | 0.00 |
Gross Profit | NA | NA | NA | NA | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 3.64 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -3.64 |
Non-Operating Income | NA | NA | NA | NA | 0.06 |
Interest Expense | NA | NA | NA | NA | 0.31 |
Pretax Income | NA | NA | NA | NA | -3.89 |
Income Taxes | NA | NA | NA | NA | 0.00 |
Minority Interest | NA | NA | NA | NA | 0.00 |
Investment Gains/Losses | NA | NA | NA | NA | 0.00 |
Other Income/Charges | NA | NA | NA | NA | 0.00 |
Income From Cont. Operations | NA | -2.95 | 0.78 | -5.23 | -3.89 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.95 | 0.78 | -5.23 | -3.89 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 18.44 | 12.46 | 11.88 | 11.79 |
Diluted EPS Before Non-Recurring Items | NA | -0.16 | 0.10 | -0.44 | -0.33 |
Diluted Net EPS (GAAP) | NA | -0.16 | 0.10 | -0.44 | -0.33 |